<DOC>
	<DOCNO>NCT01879163</DOCNO>
	<brief_summary>This Phase I trial evaluate safety immunogenicity MVA85A-IMX313 vaccination compare MVA85A vaccination , BCG vaccinate adult .</brief_summary>
	<brief_title>Phase I Trial Evaluating Safety Immunogenicity MVA85A-IMX313 Compared MVA85A BCG Vaccinated Adults</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<criteria>Subjects must meet follow criterion enter trial : Healthy adult age 1855 year Resident near Oxford ( CCVTM ) Birmingham ( WTCRF ) able travel Oxford vaccination duration trial period No relevant finding medical history physical examination Confirmation prior vaccination BCG le 6 month prior project trial vaccination date ( visible BCG scar examination write documentation ) Allow Investigators discuss individual 's medical history GP Use effective contraception duration trial period ( female ) Refrain blood donation trial Give write informed consent Allow Investigator register subject detail confidential database prevent concurrent entry clinical trial Able willing ( Investigator 's opinion ) comply trial requirement Subjects must meet none follow criterion enter trial : Laboratory evidence screen latent M. tb infection indicate positive ELISPOT response ESAT6 CFP10 antigens Clinical , radiological , laboratory evidence current active TB disease Previous vaccination candidate vaccine MVA85A candidate vaccine FP85A recombinant MVA vaccine Clinically significant history skin disorder , allergy , immunodeficiency ( include HIV ) , autoimmune disease , cancer ( except BCC CIS ) , cardiovascular disease , respiratory disease , gastrointestinal disease , liver disease , renal disease , endocrine disorder , neurological illness , psychiatric disorder , drug alcohol abuse History serious psychiatric condition Concurrent oral systemic steroid medication concurrent use immunosuppressive agent History anaphylaxis vaccination allergy likely exacerbate component trial vaccine , include egg Any abnormality screen blood urine test deem clinically significant may compromise safety subject trial Positive HBsAg , HCV HIV antibody Female currently lactate , confirmed pregnancy intention become pregnant trial period Use investigational medicinal product nonregistered drug , live vaccine , medical device trial vaccine 30 day prior dose trial vaccine , plan use trial period Administration immunoglobulins and/or blood product within three month precede plan trial vaccination date Any significant disease , disorder , finding , , opinion Investigator , may either put subject risk may influence result trial may affect subject 's ability participate trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Vaccine</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>